Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 4
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib in chronic myeloid leukemia.
Assanto GM, Scalzulli E, Breccia M. Assanto GM, et al. Drugs Today (Barc). 2022 Oct;58(10):479-489. doi: 10.1358/dot.2022.58.10.3441853. Drugs Today (Barc). 2022. PMID: 36305542 Review.
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Assanto GM, Del Giudice I, Della Starza I, Soscia R, Cavalli M, Cola M, Bellomarino V, Di Trani M, Guarini A, Foà R. Assanto GM, et al. Front Oncol. 2023 Mar 14;13:1152467. doi: 10.3389/fonc.2023.1152467. eCollection 2023. Front Oncol. 2023. PMID: 36998457 Free PMC article. Review.
Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC-K. pneumoniae. A 7-Years Retrospective Observational Cohort Study.
Micozzi A, Minotti C, Capria S, Cartoni C, Trisolini SM, Assanto GM, Barberi W, Moleti ML, Santilli S, Martelli M, Gentile G. Micozzi A, et al. Among authors: assanto gm. Infect Drug Resist. 2023 Jan 31;16:695-704. doi: 10.2147/IDR.S393802. eCollection 2023. Infect Drug Resist. 2023. PMID: 36747900 Free PMC article.
Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study.
Assanto GM, Totaro M, Poggiali R, Delli Paoli A, Annechini G, D'Elia GM, Aji F, Petrucci L, Fazio F, Del Giudice I, Martelli M, Micozzi A, Gentile G. Assanto GM, et al. Mediterr J Hematol Infect Dis. 2023 Nov 1;15(1):e2023061. doi: 10.4084/MJHID.2023.061. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 38028390 Free PMC article. No abstract available.
18 results